CoLucid Pharmaceuticals Announces Pricing of Public Offering of Common Stock
09 sept. 2016 09h15 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Sept. 09, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (“CoLucid”) (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute...
CoLucid Pharmaceuticals Announces Proposed Public Offering of Common Stock
08 sept. 2016 16h01 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Sept. 08, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (“CoLucid”) (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute...
CoLucid Pharmaceuticals Announces Achievement of Both Primary and Key Secondary Endpoints in the SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine
06 sept. 2016 07h00 HE
|
CoLucid Pharmaceuticals, Inc
100 mg and 200 mg doses of lasmiditan efficacious on headache pain freedom and most bothersome symptom free at the two-hour time point (p < 0.001)Lasmiditan was well tolerated with no significant...
CoLucid Pharmaceuticals Announces 2016 Second Quarter Results and Corporate Highlights
10 août 2016 08h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the quarter ended June 30, 2016. Corporate...
CoLucid Pharmaceuticals Hosting Key Opinion Leader Meeting in New York City
22 juin 2016 16h01 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc., (Nasdaq:CLCD) a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the...
CoLucid Pharmaceuticals Announces Last Patient Randomized in SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine
07 juin 2016 08h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the...
CoLucid Pharmaceuticals to Participate at the Jefferies 2016 Healthcare Conference
02 juin 2016 08h58 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the...
CoLucid Pharmaceuticals Announces Initiation of Second Phase 3 Pivotal Trial of Lasmiditan in Migraine
19 mai 2016 12h46 HE
|
CoLucid Pharmaceuticals, Inc
First Patient Randomized in SPARTAN StudyTrial Being Conducted Under Special Protocol Assessment Agreement with FDA CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals,...
CoLucid Pharmaceuticals Announces 2016 First Quarter Results and Corporate Highlights
11 mai 2016 16h01 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the first quarter ended March 31, 2016. Corporate...
CoLucid Pharmaceuticals Announces Election of Alison Lawton to Board of Directors
15 mars 2016 08h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., March 15, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...